Chronically mad as a hatter: Anticholinergics and Alzheimer's disease pathology
- 25 July 2003
- journal article
- Published by Wiley in Annals of Neurology
- Vol. 54 (2), 144-146
- https://doi.org/10.1002/ana.10667
Abstract
No abstract availableThis publication has 8 references indexed in Scilit:
- Increased Alzheimer pathology in Parkinson's disease related to antimuscarinic drugsAnnals of Neurology, 2003
- The Amyloid Hypothesis of Alzheimer's Disease: Progress and Problems on the Road to TherapeuticsScience, 2002
- The selective muscarinic M1 agonist AF102B decreases levels of total A? in cerebrospinal fluid of patients with Alzheimer's diseaseAnnals of Neurology, 2000
- Treatment with the Selective Muscarinic Agonist Talsaclidine Decreases Cerebrospinal Fluid Levels of Total Amyloid β‐Peptide in Patients with Alzheimer's DiseaseAnnals of the New York Academy of Sciences, 2000
- In Vivo Regulation of Amyloid Precursor Protein Secretion in Rat Neocortex by Cholinergic ActivityEuropean Journal of Neuroscience, 1997
- Muscarinic acetylcholine receptor expression in memory circuits: Implications for treatment of Alzheimer diseaseProceedings of the National Academy of Sciences, 1996
- Activation of m1 Muscarinic Acetylcholine Receptor Regulates τ Phosphorylation in Transfected PC12 CellsJournal of Neurochemistry, 1996
- Release of Alzheimer Amyloid Precursor Derivatives Stimulated by Activation of Muscarinic Acetylcholine ReceptorsScience, 1992